Abstract
Active immunization with the B-lymphocyte stimulating HER2 vaccine, IMU-131 (HER-Vaxx), has shown clinical response correlated with HER2-specific antibodies (Wiedermann et. al., Annals of Oncology, 2019). The IMU-131 HERIZON study is based on the landmark ToGA study (Bang et. al., The Lancet, 2010) and included patients with HER2/neu overexpressing metastatic or advanced gastric/GEJ cancer who were naïve to HER2 therapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
